Downregulation of SS18-SSX1 expression by small interfering RNA inhibits growth and induces apoptosis in human synovial sarcoma cell line HS-SY-II in vitro

European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)
Chang-Liang PengHui Zhao

Abstract

Substantial evidence indicates that the characteristic SS18-SSX fusion gene may play an important role in synovial sarcoma development and progression. For obtaining better insights into the genetic alterations and molecular mechanisms involved in synovial sarcomas and for developing novel therapeutic strategies for this disease, we first examined the efficiency of small interfering RNAs (siRNAs) targeting the SS18-SSX1 fusion gene in knocking down its expression in the human synovial sarcoma cell line HS-SY-II, and then evaluated the effects of downregulation of this gene on apoptosis, apoptosis-related gene expression, growth regulatory proteins, and the growth of tumor cells in vitro. We observed a marked decrease (by more than 87.6%) in SS18-SSX1 expression levels in cells transfected with a plasmid expressing hairpin siRNA for this gene, which was accompanied by (i) reduction in protein levels of cyclin D1 and cyclin A, (ii) reduction in antiapoptotic protein Bcl-2 and activation of caspase 3/apoptosis, and (iii) growth inhibition of HS-SY-II cells in vitro. Our results demonstrate that siRNA targeting of SS18-SSX1 may have therapeutic potential in the treatment of synovial sarcomas.

References

Jan 15, 1998·The New England Journal of Medicine·A KawaiM Ladanyi
Jun 8, 1999·Journal of the National Cancer Institute·B SkyttingO Larsson
May 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J J LewisM F Brennan
Dec 7, 2000·Genes, Chromosomes & Cancer·N R dos SantosA G van Kessel
Aug 29, 2001·Nature Structural Biology·P D Zamore
Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
Mar 14, 2002·Cancer Genetics and Cytogenetics·Avery A Sandberg, Julia A Bridge
May 10, 2002·Nucleic Acids Research·Olivier Donzé, Didier Picard
Dec 10, 2002·Current Opinion in Chemical Biology·Reuven Agami
May 14, 2003·Molecular and Biochemical Parasitology·Jon P BoyleTimothy P Yoshino
Jul 9, 2004·Nature·Carl D Novina, Phillip A Sharp
May 9, 2006·European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)·Baocun SunXishan Hao

❮ Previous
Next ❯

Citations

Mar 8, 2012·Molekuliarnaia biologiia·T V KekeevaG A Frank
May 30, 2013·Clinical Orthopaedics and Related Research·Emily E Carmody SoniJeffrey A Toretsky
Jan 19, 2013·Medical Oncology·Monica CantileGerardo Botti
Jun 24, 2016·Annals of Surgical Oncology·Myrella VlenterieWinette T A van der Graaf
Sep 12, 2013·British Journal of Cancer·T RenY Sun
Mar 14, 2018·International Journal of Oncology·Changliang PengChunzheng Gao
Apr 23, 2020·Sarcoma·Kirill I KirsanovMarianna G Yakubovskaya
Nov 5, 2020·Epigenetics & Chromatin·Sarah M Innis, Birgit Cabot
May 25, 2021·Molecular & Cellular Oncology·Christina Cooley, Le Su

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis